Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Immix Biopharma, Inc.

NASDAQ: IMMX · Life Sciences · 4 alerts · CIK 1873835

Share price
$7.48Close, Nov 16
Market cap
$627M
Shares outstanding
83.81MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immix Biopharma, Inc. filings on SEC EDGAR ↗

4:16 PM ET 8-K
Business Update

Immix Biopharma Business Update

Immix Biopharma reported its Q3 2026 operational progress, highlighting an 89% complete response rate in its NEXICART-2 clinical trial for NXC-201. The company strengthened its leadership team with new SVPs of Technical Operations and Regulatory Affairs as it prepares for a planned BLA submission in mid-2027.

4:07 PM ET 10-Q
Financial Results

Immix Biopharma Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Immix Biopharma, Inc. reported a significant increase in cash and cash equivalents to $320.3 million as of September 30, 2026, compared to $93.9 million at year-end 2025. The company's accumulated deficit grew to $140.0 million, driven by nine-month operating expenses including $22.4 million in general and administrative costs and $16.9 million in research and development.

Key figure
Net loss $13.9M
5:11 PM ET 8-K
Capital Raise

Immix Biopharma Capital Raise of $125M

Immix Biopharma priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, generating gross proceeds of $125 million. The company intends to use the net proceeds to fund the development of its CAR-T cell therapy NXC-201, working capital, and general corporate purposes.

Value
$125M
Counterparty
J.P. Morgan Securities LLC
7:00 AM ET 8-K
Clinical Trial Data

Immix Biopharma Clinical Trial Data

Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.

Earnings call
Sep 29, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.